LOTIVIBART
UNII CV5TGS48YN

Substance Identification & Data

This profile provides standardized clinical and technical data for Lotivibart, uniquely identified by the FDA Unique Ingredient Identifier (UNII) CV5TGS48YN.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2851892-98-1 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

CV5TGS48YN

CAS Registry Number

2851892-98-1

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

LOTIVIBART

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C211700

National Cancer Institute reference terminology for clinical and research data.

INN ID

13158

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

NO-248

Identifier assigned by the United States Adopted Names Council.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Lotivibart. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

LOTIVIBART

Common Names & Synonyms

GSK 3810109A [WHO-DD]

H-GAMMA1 HEAVY CHAIN HOMO SAPIENS (1-452) (VH (HOMO SAPIENS IGHV1-2*02 (59.2%) -(IGHD) -IGHJ1*01 (72.7%) L123>T (117), T125>V (119), S128>A (122), CDR-IMGT (8.8.15) (26-33.51-58.97-111)) (1-122) -HOMO SAPIENS IGHG1*01, G1M17,1 CH1 K120, CH3 D12, L14, G1V24 CH3 L107, S114 (CH1 K120 (219) (123-220), HINGE 1-15 (221-235), CH2 (236-345), CH3 D12 (361), L14 (363), M107>L (433), N114>S (439) (346-450), CHS (451-452)) (123-452)), (225-210')-DISULFIDE WITH L-KAPPA LIGHT CHAIN HOMO SAPIENS (1'-210') (V-KAPPA (HOMO SAPIENS IGKV1-13*02 (69.6%) -IGKJ5*01 (70.0%) Q120>R (96'), T122>S (98'), E1125>H (101'), CDR-IMGT (6.3.5) (27'-32'.50'-52'.89'-93')) (1'-103') -HOMO SAPIENS IGKC*01 (100%) KM3 A45.1, V101 (CKAPPA A45.1 (149'), V101 (187')) (104'-210')); DIMER (231-231'':234-234'')-BISDISULFIDE, PRODUCED IN CHINESE HAMSTER OVARY (CHO) CELLS, CELL LINE CHO-DG44, GLYCOFORM ALFA

IMMUNOGLOBULIN G1 (433-LEUCINE,439-SERINE), ANTI-(HUMAN IMMUNODEFICIENCY VIRUS RETROVIRAL ENVELOPE GLYCOPROTEIN GP120ENV CD4-BINDING SITE) (HUMAN CLONE VH3810109 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN CLONE VH3810109 .KAPPA.-CHAIN, DIMER

IMMUNOGLOBULIN G1-KAPPA, ANTI-(HIV-1 (HUMAN IMMUNODEFICIENCY VIRUS TYPE 1) GP120 ENVELOPE GLYCOPROTEIN, CD4-BINDING SITE), HOMO SAPIENS MONOCLONAL ANTIBODY

LOTIVIBART [INN]

LOTIVIBART [USAN]

N6LS

N6LS (RECOMBINANT HUMAN IMMUNOGLOBULIN G1 DIRECTED AGAINST THE CD4-BINDING SITE OF THE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) GLYCOPROTEIN 120)

VRC-HIVMAB091-00-AB